AXNX News and Press, Axonics Modulation Technologies Inc. From 02/22/23

Summary Axonics presents with robust fundamentals and unit economics around its sacral neuromodulation segment. The company confirmed FY22 numbers above consensus, guides to FY23E revenues above the Street as well. Shares attractive given top-line growth rates, current sales multipl...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter 2022 financial results after the close of trading on Wednesday, March 1. Axonics will host a c...

The U.S. Food and Drug Administration (FDA) approved Axonics ( NASDAQ: AXNX ) fourth-generation rechargeable sacral neuromodulation system (SNM). SNM is a therapy to treat urinary incontinence. The company said Axonics R20 neurostimulator is labeled for a functional life in t...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug Administration has approved the company’s fourth-generation rechargeable s...

Axonics ( NASDAQ: AXNX ) expects 4Q total net revenue to be range in  $85.6M to $86.0M, an increase of 61% Y/Y, vs consensus of $74.30M . Q4 Sacral neuromodulation revenue is expected to be $70.2M to $70.4M, an increase of 58% Y/Y. Q4 Bulkamid revenue is expected to b...

4Q22 total company net revenue expected to be $85.6 to $86.0 million, an increase of 61% y/y Fiscal year 2022 total company net revenue expected to be in the range of $273.6 million, an increase of 52% y/y Fiscal year 2023 revenue guidance of $342 million, an increase of 25% y/y ...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California. Axonics is scheduled to p...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Health Canada has approved the company’s fourth-generation rechargeable sacral neuromodulation sy...

Vir Biotechnology (NASDAQ: VIR) and Axonics (NASDAQ: AXNX) are two of the fastest-growing healthcare companies in terms of revenue. Vir raised $142.9 million when it went public with an initial public offering (IPO) in 2019, while Axonics raised $120 million with its IPO in 2018...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will participate in the Piper Sandler Healthcare Conference on December 1, 2022. Axonics is scheduled to presen...